Lupus Research Alliance Sign Up Information

Join Our Events | Resource Center | Lupus Community

Members of Congress are heading back home for August recess -- the perfect time for you to request a meeting!

As a member of the lupus community, you share our goal – to enlist support from the federal government for issues that can help people with lupus. So, become your legislators’ go-to person on all things lupus! Make an appointment to meet in their local office to tell them about your experience with the disease and why federal funding for lupus research is so important.

Here’s a guide for how to arrange, prepare for, conduct, and follow-up on a meeting with your legislator.

You’ll also learn ways to use this intro meeting as the first step in building a relationship with members of Congress that can influence how lupus research is funded in the future.

From the Lupus Research Alliance, the world’s leading authority in lupus research.

Donate ?

PALS Clinical Trial Program Opens at Five Universities

In five pilot cities, people with lupus who are starting to think about taking part in a clinical trial can now join the Patient Advocates for Lupus Studies (PALS) program created by LRA's affiliate Lupus Therapeutics.

The program will pair adults with lupus interested in learning about clinical trials with a peer or “PAL” who has lupus, has been in a clinical study, and who has been trained through the PALS program to discuss clinical trials.

Kudos to GSK’s Daemion Johnson for Prestigious Recognition as a Patient Advocate

LRA congratulates Daemion T. Johnson – GSK’s Director, Patient Engagement. He was recognized by the prestigious magazine PharmaVOICE.com as one of the 100 people in the life-sciences industry who “provide inspiration to their peers, colleagues, and companies...”

We are proud to have the opportunity to work with Daemion on behalf of the lupus community. The LRA participated with an innovative and fun national education series that Daemion came up with -- the Night of Beauty events.

It’s August Recess for Congress -- Meet Members in Their Local Offices

The Lupus Research Alliance is the world’s leading authority in lupus research thanks to your support. Please donate today.

Donate ?

RESEARCH NEWS

LRA Collaborates with Celgene on Bold New Research

The Lupus Research Alliance (LRA), the largest private funder of lupus research in the world, is very pleased to announce a unique new partnership with Celgene Corporation that provides $3,000,000 for bold, cutting-edge research projects.

This opportunity will focus on addressing lupus heterogeneity -- how much the disease varies from person to person -- and identifying novel biomarkers to monitor disease activity.

New Biomarker Research Fast-Tracked

Progentec Diagnostics announced it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant of $1.7 million to see how well lab tests based on biomarkers in the blood can measure and predict active disease.

Biomarkers are critical to diagnosing and monitoring your lupus as well as predicting and potentially preventing flares. The LRA has invested in more than 20 projects to find and test effective biomarkers. Our most recent grants for promising biomarkers went to Dr. Virginia Pascual and Dr. Andrea Knight. We're on it!

LRA-Funded Discovery May Benefit Alzheimer's Disease

A new study by LRA grant recipient Dr. Douglas Green and colleagues may have uncovered a new way to treat Alzheimer’s disease.

“This study illustrates the synergies we foster across diseases,” commented Teodora Staeva, PhD, Chief Scientific Officer of the Lupus Research Alliance.

CLINICAL TRIAL NEWS

Clinical Trial of New Molecule Discovered Thanks to LRA Funding Has Finished Enrollment

Resolve Therapeutics announced that it has enrolled enough patients to conduct a Phase 2a study of a potential treatment for lupus, RSLV-132. A grant from the Lupus Research Alliance to Dr. Keith Elkon supported the early work that led to the creation of the molecule RSLV-132.

Stay tuned for updates!

The Lupus Research Alliance is the world’s leading authority in lupus research thanks to your support. Please donate today.

National Immunization Month - Take the Right Shots!

While August is when we savor the last weeks of summer, it is also the time to look ahead and prepare for fall. In recognition of National Immunization Month, our Chief Scientific Officer provides background on vaccines and relays government recommendations for which are safe for people with lupus.

It's critical to consult with your healthcare provider before taking any vaccine.

Congress is Still on Recess -- Meet Your Legislators in Their Local Offices

There's still time - so don't miss the opportunity to advocate for lupus with your representatives and senators.

The Lupus Research Alliance is the world’s leading authority in lupus research thanks to your support. Please donate today.

Exagen to Further LRA-Supported Research into Ways to Diagnose and Monitor Lupus

Great News! Critical research supported by the Lupus Research Alliance has led to an exciting research collaboration between the funded scientist Dr. Christian Lood, University of Washington and Exagen Inc. Together they will study if certain biomarkers can help diagnose and predict the course of disease so people with lupus can be treated quickly and appropriately.

With your help, more discoveries that lead to the development of better ways to diagnose and treat lupus are on the way. We appreciate your continued support!

New Research Shows Benlysta® Reduces B Cells – Common Culprits in Lupus

Newly published research found that belimumab (Benlysta®) effectively reduced the number of B cells, a type of white blood cell that in lupus makes destructive antibodies.

Earlier breakthroughs by two scientists funded by one of the Lupus Research Alliance heritage organizations helped set the stage for the development of belimumab.

The Lupus Research Alliance is the world’s leading authority in lupus research thanks to your support. Please donate today.

MOMENTOUS NEWS -- Potential New Lupus Treatment Effectively Reduced Disease Activity in Phase III Trial

The Lupus Research Alliance is excited to share the good news that a potential new medicine for lupus, anifrolumab, reduced disease activity versus placebo in a second Phase III study. More than 15 studies funded by the Lupus Research Alliance over the past decade into the role of type I interferons and inflammation were pivotal to the eventual development of anifrolumab.

“It is tremendously gratifying to learn of this important success,” commented Dr. Mary Crow, Co-chair of the Lupus Research Alliance Scientific Advisory Board (SAB) and Physician-in-Chief/Chair of Department of Medicine at Hospital for Special Surgery and Chief of Rheumatology at HSS and NewYork-Presbyterian/Weill Cornell Medical Center. “The Lupus Research Alliance has made significant investments in research focused on the role of type I interferons in lupus, and I am personally very excited given my own research in this area.”

Lupus Research Alliance President and CEO Kenneth M. Farber noted, “These positive results from a pivotal Phase III trial are very hopeful for people with lupus who have waited years for desperately needed new treatment options. We look forward to seeing the full results of the study and further progress in evaluating anifrolumab as a potential therapy.”

The Lupus Research Alliance is the world’s leading authority in lupus research thanks to your support. Please donate today.

New York Jets Kick Off 2019 Season with a Blitz Attack on Lupus

The Lupus Research Alliance was proud to help launch the upcoming season at the New York Jets 20th Annual Kickoff Luncheon that raised hundreds of thousands for lupus research.

Breakthrough in MS Sheds Light on Autoimmune Disease, Including Lupus

LRA Research Committee member Dr. Mark Davis recently published an important paper that may transform how scientists view autoimmune diseases, including lupus.

The Lupus Research Alliance is the world’s leading authority in lupus research thanks to your support. Please donate today.

A new study partly funded by the Lupus Research Alliance (LRA) may help explain how the immune system attacks patients’ DNA in lupus. Together with the laboratory of Dr. David Raulet at the University of California, Berkeley, Dr. Joshua Woodward of the University of Washington in Seattle and his colleagues discovered a protein door in cells that allows messenger molecules that may promote these attacks to spread.

From the Lupus Research Alliance, the world’s leading authority in lupus research.

Treat-to-Target is Feasible and Beneficial in Lupus

Treating patients with lupus until they reach specific health goals can reduce disease flares and prevent organ damage, according to a research team co-led by Dr. Eric F. Morand, who is a past recipient of the Distinguished Innovator Award from the Lupus Research Alliance.

This study is important because it provides specific standards that allow doctors to see how well lupus treatment is working and to predict the long-term prognosis for patients.

FDA Expedites Existing Drug for Lupus Nephritis

The LRA is pleased to share that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Gazyva® (obinutuzumab) for adults with lupus nephritis.

Breakthrough Therapy Designation aims to speed up the development and review of drugs that are intended to treat a serious condition when “preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).”

Gazyva® is an existing drug from the Roche Group that is approved by the FDA for treating certain types of cancer.

The Lupus Research Alliance is the world’s leading authority in lupus research thanks to your support. Please donate today.

Super Duel For a Super Prize

Tackle Lupus to Win a Trip to Super Bowl LIV

Suit up and make a difference on Game Day! Help us blitz lupus and compete in this week's FanDuel* NFL scheduled games on Sunday, September 29^th in the Super Bowl Duel for a Difference! Only Sunday’s games are eligible for the contest.

The Winner will receive an unforgettable Grand Prize -- Two Tickets and hotel for Super Bowl LIV in Miami.

Use our special link (www.fanduel.com/lupus) to play, and your $3 entry fee will go directly to the Lupus Research Alliance. Please put LUPUS in the promo code section when you sign up.

And share the link www.fanduel.com/lupus - with your friends and family on Facebook, Twitter and Instagram. The more people who duel, the greater difference we can make! Help us go on the offense against lupus and score a big win for the millions hoping for a cure!

Thanks for your support!

Sincerely,

Lupus Research Alliance

For more information or questions about this contest, please feel free to contact Jonathan Marks at jmarks@lupusresearch.org with any questions.

* FanDuel is the leader in one-day fantasy sports.

The Lupus Research Alliance is the world’s leading authority in lupus research.

Accelerating Medicines Partnership Completes Key Phase

The Accelerating Medicines Partnership (AMP) RA/Lupus Program, a joint effort involving the National Institutes of Health (NIH), the Foundation for NIH, pharmaceutical companies, and non-profit organizations such as the Lupus Research Alliance, has reached a milestone, finishing an important phase of its studies. Researchers with the AMP RA/Lupus Program have published a summary report on their findings from this stage, which include identifying kidney cells that may predict if patients will respond to treatment and discovering immune cells that may promote the disease.

Nearly One-third of People with Lupus Treat Their Pain with Opioids

In a newly published Michigan study, nearly 1 in 3 adults with systemic lupus erythematosus used prescription opioids to treat pain despite lack of evidence that opioids effectively reduce pain from lupus and rheumatic diseases.

Blogger Writes About Taking Hope from Lupus Research

The Lupus Research Alliance is the world’s leading authority in lupus research thanks to your support. Please donate today.

LRA Pleased to Share News of New Lupus Nephritis Trial

The Lupus Research Alliance is pleased to share news about the launch of EQUALISE, a Phase 1b trial that will evaluate the safety and tolerability of an experimental compound itolizumab at various doses in a small group of patients with systemic lupus erythematosus (SLE) and lupus nephritis.

The LRA played an important role in the trial design and initiation, making sure that the patient perspective was well represented. The organization reviewed educational materials about the trial and enlisted people living with lupus and/or lupus nephritis to also provide feedback.

Save the Date - 2019 Breaking through Lupus Gala

Monday, November 25, 2019

6:30 pm Cocktails / 7:30 pm Dinner and Awards Presentation

Ziegfeld Ballroom

141 West 54th Street, New York City

Honoring

Alfred F. Kelly, Jr. / Chairman and Chief Executive Officer, Visa Inc.

Molly McCabe / Co-Founder, the former Molly's Fund Fighting Lupus, Lupus Community Leader

Host

Brenda Blackmon / Emmy-Winning Journalist

Entertainment

Laura Benanti / Tony Award-Winning Actress and Singer

The Lupus Research Alliance is the world’s leading authority in lupus research thanks to your support. Please donate today.

Win a super prize in a super duel!

Don’t Miss Your Chance to Win a Trip to Super Bowl LIV

Tomorrow is Game Day! Help us blindside lupus by playing this week's FanDuel* NFL scheduled games Sunday, September 29 in the Super Bowl Duel for a Difference!

Only Sunday’s games are eligible for the contest.

You could win the grand prize Tickets to the BIG GAME and hotel accommodations for two at Super Bowl LIV in Miami! But you’ve got to be in it to win it!

Use our special link (www.fanduel.com/lupus) to play, and your $3 entry fee will go directly to the Lupus Research Alliance. Please put LUPUS in the promo code section when you sign up.

And please share the link www.fanduel.com/lupus with your friends and family on Facebook, Twitter and Instagram. The more fans who compete, the more we can make a difference for millions around the world! Let’s play and score a touchdown in the fight against lupus!

Thanks for your support!

Sincerely,

Lupus Research Alliance

For more information or questions about this contest, please feel free to contact Jonathan Marks at jmarks@lupusresearch.org with any questions.

* FanDuel is the leader in one-day fantasy sports.

The Lupus Research Alliance is the world’s leading authority in lupus research.

16th Annual Lupus Meeting and
Advocate for Lupus Research Day

March 9-10, 2020
Washington, DC

• Do you want to learn about important legislative issues for people with lupus?
• Do you want new treatments and a cure for lupus?
• Do you want to make a difference for people with lupus?

Join us on The Hill and speak your mind to Congress!

Every March for the past 15 years, the Lupus Research Alliance has hosted an Annual Lupus Meeting and Advocate for Lupus Research Day in Washington, DC. The two-day event is your chance to learn about legislative issues impacting the lupus community and to convey to Congress the importance of budgeting funds for lupus research.

On Monday, March 9, you will learn the issues and train to convey them. On Tuesday, you will meet with members of Congress and/or their staff.

For 2020, we are offering an opportunity to attend in two ways:

1. Apply to attend by completing the application at the link below to be eligible for either a scholarship from the PA Fund for Patient Advocacy or grant support from the Lupus Research Alliance

2. Pay your own way (register during general registration)

To apply for scholarship and grant opportunities, please click here

Application Deadline: October 21, 2019 at 5:00pm ET

The Lupus Research Alliance is the world’s leading authority in lupus research. With your support we'll continue to fund the most promising research. Please donate today.

Join Us Today!

One Line, One Day is a national social media initiative born from the Lupus Research Alliance’s Multicultural Outreach Task Force. The goal of One Line, One Day is to reach groups of people most affected by lupus with messages of hope about lupus research. The campaign also provides tools to understand more about the signs of lupus and engages individuals in fundraising efforts to make a difference.

Today we ask you to join us in sharing the message: Millions worldwide are affected by lupus. Scientific research is the most powerful way we can improve the lives of people living with lupus, today and over the long term. #OneLineOneDay lupusresearch.org

By working together with the entire lupus community, we will accomplish our mission to find a cure for lupus. Share this message to spread awareness on Twitter, Facebook, and Instagram.

The Lupus Research Alliance is the world’s leading authority in lupus research.

Find out:

• How our affiliate Lupus Therapeutics has achieved the unobtainable. Read More
• Why world-renowned expert Dr. Daniel Wallace joined the Board of Lupus Therapeutics. Read More
• Who are our PALS? Read More
• What trials can you join? Read More
• And other exciting news to transform the lives of people with lupus. Read More

The Lupus Research Alliance is the world’s leading authority in lupus research.

New Directions for Lupus Treatment Presented at LRA’s 2019 Forum for Discovery

More than 100 of the world’s top scientists in lupus research and treatment gathered at the LRA’s 2019 annual, three-day Forum for Discovery scientific conference. The meeting centered mainly on fundamental research, probing why immune cells in lupus don’t function correctly, explaining organ damage, and exploring potential treatment strategies that include adding high fiber to your diet.

Researchers shared their promising discoveries, funded by the LRA, sparking dynamic discussion and exchange of ideas that may well lead to the next breakthrough. This newsletter brings just some of the highlights. More to come!

Lupus Insight Prize Presented for Work Directed at Personalized Treatment

Dr. Ignacio Sanz received this year’s Lupus Insight Prize from current Scientific Advisory Board (SAB) co-chair Dr. Gary Koretzky for exciting work aiming to answer why lupus is such a complicated chronic disease – why it affects every patient so differently and how treatment can be tailored to each person.

LRA’S 2019 AWARDS OF UP TO $1 MILLION AIMED AT NEW LUPUS TREATMENTS

LRA proudly announced at our 2019 Annual Scientific Conference two exceptional recipients of the 2019 Distinguished Innovator Award: Fabienne Mackay, PhD, and Jeffrey Rathmell, PhD.

Dr. Mackay and her team at University of Melbourne are testing a novel combination approach to reverse lupus in mice. With his colleagues at Vanderbilt University, Dr. Rathmell will test two drugs being developed for cancer that target cells’ metabolism to find out if they reduce lupus symptoms in mice.

LRA SALUTES DR. Mary CROW FOR OUTSTANDING SERVICE AS SCIENTIFIC ADVISORY BOARD CO-CHAIR

LRA President and CEO Kenneth Farber expressed tremendous appreciation as he announced that Dr. Mary Crow’s term as Co-chair of our Scientific Advisory Board (SAB) concludes December 31 when Dr. Gary Koretzky will assume full responsibility as sole Chair.

“We are enormously grateful to Dr. Crow for the vision, leadership and expertise she has brought to the organization for more than a decade,” Mr. Farber commented. “Although she is stepping down as co-chair, we are fortunate that Dr. Crow will continue to work with the LRA in several other capacities.”

Read Dr. Crow’s bio to understand how much she brings to the organization.

The Lupus Research Alliance is the world’s leading authority in lupus research.

Lupus Research Alliance Invests More Than $3.5 Million in Grants to Spark New Treatments

The Lupus Research Alliance has announced the recipients of its Target Identification in Lupus grants, which are designed to accelerate the development of promising discoveries into potential therapies.

The grants enable scientists to address fundamental questions in lupus research and remove barriers to the development of new treatments. The six awardees, who receive up to $600,000 each, are testing innovative approaches for combating lupus that include shutting off a switch for kidney inflammation, reducing cellular stress, and preventing development of harmful immune cells.

2019 Grant Recipients

Montserrat Anguera, PhD, University of Pennsylvania School of Veterinary Medicine, will test whether genes that normally shut off in women’s cells turn back on in lupus, causing the immune system to malfunction.

Paolo Casali, MD, University of Texas Health Science Center at San Antonio, will probe whether two enzymes are harmful or beneficial in lupus and identify new potential treatments that target the enzymes.

Hongbo Chi, PhD, St. Jude Children's Research Hospital, will study follicular T cells, which are culprits in lupus, to find out if their unique metabolism has a role in the disease.

Hui-Chen Hsu, PhD, University of Alabama at Birmingham, will test whether the combination of two immune system molecules can prevent B cells, which promote lupus symptoms, from becoming harmful.

Vicki Kelley, PhD, Harvard Medical School, has discovered a possible master switch for kidney inflammation and will determine whether shutting it off or removing it protects the kidneys.

Jason Knight, MD, PhD, University of Michigan, will investigate the role of a type of cell stress in lupus and whether shutting off a cellular stress detector quells the disease’s symptoms.

“These projects hold great promise in identifying new directions for developing potential treatments for lupus, and we look forward to their results," noted Teodora Staeva, PhD, Chief Scientific Officer of the Lupus Research Alliance.

The awards support research to identify and investigate molecular pathways and therapeutic targets that will lead to new therapies or improved management for patients with lupus.

Only with your help can we support the research that brings breakthroughs. Donate now to make even more progress possible.

The Lupus Research Alliance is the world’s leading
authority in lupus research.

Raising Thousands for Lupus Research;
Running the NYC Marathon for Life Without Lupus

Big thanks go to our Team Life Without Lupus, who put their passion and energy into running the TCS New York City Marathon Sunday to raise $65,000 and climbing for lupus research. Here’s the team at our pre-Marathon Pasta Party, powering up with energy-boosting carbs!

The team starred two people living with lupus -- Amy Cargain and Kia Adams -- who ran despite the challenge of the disease.

Amy’s triumph caught the attention of two media outlets Fox5 NY and News12 Westchester, raising awareness of the need for lupus research. 

Many others ran on behalf of someone special with lupus. One group gathered family from around the world to run in honor of Aunt Regina (Weitzman) who has lived more than 25 years with lupus.

Their inspirational story captivated New York reporters from CBS New York, Good Day New York on Fox5, the New York Post and News 12 Bronx.

You can show your appreciation and support for our team’s dedication to lupus research with a donation to boost their fundraising! Let’s aim higher so the Lupus Research Alliance can keep breaking through until Amy, Kia, Regina and the millions more worldwide can enjoy Life Without Lupus.

The Lupus Research Alliance is the world’s leading authority in lupus research.

Lupus Research Alliance Invests $1.8 Million in Cutting-Edge Discovery

The Lupus Research Alliance has awarded Novel Research Grants totaling $1.8 million to five top-notch scientists working to discover why the immune system malfunctions in lupus and how to restore it to normal.

2019 Novel Research Grantees

Carla Cuda, PhD, Northwestern University Feinberg School of Medicine, will investigate whether the immune cells known as microglia are responsible for the brain symptoms of lupus.

Anne Davidson, MBBS, Feinstein Institutes for Medical Research, will test whether certain immune cells promote inflammation in lupus because the internal clocks that control when they are active are wrong.

Neelakshi Jog, PhD, Oklahoma Medical Research Foundation, will determine whether the body produces too many immature neutrophils, a type of immune cell, in patients with lupus.

Michelle Kahlenberg, MD, PhD, University of Michigan, will study how the activity of genes in the skin changes when patients with lupus are exposed to ultraviolet light.

Yee Ling Wu, PhD, Loyola University Chicago Health Sciences Division, will investigate whether an immune system protein whose levels are often abnormally high in lupus promotes blood clots and atherosclerosis.

The funding for these studies is thanks to the generosity of champions like you. Please consider a donation to support the next round of studies that will bring us closer to a cure.

From the Lupus Research Alliance, the world’s leading authority in lupus research.

LRA Researchers Star at ACR/ARP – Part 2

Last week we gave you only a glimpse of what scientists funded by the Lupus Research Alliance (LRA) shared at 2019 ACR/ARP. So many studies were presented that today we bring you Part 2 of the major discoveries your donations have made possible. Part 3 is yet to come!

How a Protective Protein Blocks Inflammation

Dr. Eric Morand and his team at Monash University in Australia reported his new findings about a possible drug target. The protein, called GILZ, reduces lupus symptoms by blocking the effects of molecules called type I interferons that help drive lupus symptoms.

Not All Harmful Immune Cells Are Alike

With their grant from the LRA, Dr. Timothy Niewold and colleagues at NYU School of Medicine found that there are variations of two types of cells involved in immune system attacks. Plasmacytoid dendritic cells and switched memory B cells may have important roles in the disease and could offer targets for new drugs.

New Source for Harmful Proteins

With their LRA funding, Dr. Keith Elkon and his team at the University of Washington may have found a clue to a long-standing scientific paradox in lupus -- specifically the role of proteins known as complement and whether they are beneficial, harmful, or both.

Similarity Between Inherited Vs. Non-Inherited Lupus

A study led by Dr. Boris Reizis at NYU Langone Medical Center sheds light on how a protein, DNASE1L3, that helps dispose of cellular trash, may contribute to causing lupus. In people with lupus, when the trash isn’t taken out, the immune system attacks, also destroying healthy cells in its path.

“Each of these studies point to potential targets for development of new treatments,” commented Teodora Staeva, PhD, Chief Scientific Officer at the Lupus Research Alliance. “We look forward to further study to see which are viable for clinical development.”

From the Lupus Research Alliance, the world’s leading authority in lupus research.

Lupus Research Alliance 2019 Breaking Through
Gala Raises $3 Million for Lupus Research

NYC Lights Up for Lupus Gala

The Lupus Research Alliance (LRA) 2019 Breaking Through Gala gathered 600+ members of the global lupus community to raise $3 million, all of which goes directly to lupus research. The theme, Breaking Through, celebrated the many research discoveries that LRA makes possible to transform the lives of people struggling with lupus every day.

This year’s Gala honored Alfred E. Kelly, Jr., Chairman and Executive Officer of Visa Inc. and Molly McCabe, Co-Founder of the former Molly’s Fund Fighting Lupus and current member of the LRA Board of Directors.

Honorary Co-Chairs who helped make this the world’s largest single lupus fundraising event include former NYC mayor, the Honorable Michael R. Bloomberg and Lady Gaga. In a video message, the former Mayor said, “Bloomberg Philanthropies is proud to support the Lupus Research Alliance as we have done for many years. We are sharing a simple and powerful message -- join us.”

Lady Gaga also served as Honorary Co-Chair out of love for her aunt Joanne who lost her battle with lupus before they could ever meet. Her dad Joe Germanotta sits on the Lupus Research Alliance Board of Directors.

Even New York City did its part to help raise lupus awareness in honor of the Breaking Through Gala. Yesterday, the organization had top billing on a prominent marquee in Times Square saluting its research leadership thanks to corporate supporter GSK. And last night, the world-famous Empire State Building lit up in the LRA colors -- purple and red.

Fresh from her starring role as Eliza Doolittle in My Fair Lady, Laura Benanti entertained with a medley of songs including the unforgettable, “I Could Have Danced All Night.” Emmy-winning Journalist Brenda Blackmon emceed the Gala, sharing the poignant story of her daughter’s struggle with lupus and celebrating the triumphs of all those with the disease.

The highly distinguished and hard-working group of 2019 Gala Co-chairs included: Ira Akselrad, Lynn Biggar, Richard DeScherer, Colleen Ostrowski, Robert W. Pittman, Kelly Mahon Tullier, and William J. Wolfe.

Board members pictured are: William Wolfe, William Mulvihill, Jennie and Richard DeScherer, Molly McCabe, Spencer Zwick, and Brenda Blackmon. Additional Board members who attended are: Neil Burmeister, Jerome Chazen, Katey Driscoll and Carol Weisman.

Watch this video to understand why thousands of generous members of the lupus community worldwide support the Gala and Breaking Through science funded by the Lupus Research Alliance.

Click here for full Gala coverage.

Lupus Research Alliance Applauds Phase III Trial Results for Potential Lupus Nephritis Treatment

The Lupus Research Alliance congratulates Aurinia Pharmaceuticals on achieving the first positive Phase III trial results for an urgently needed treatment for lupus nephritis. The company’s investigational drug voclosporin showed positive effectiveness and good safety with standard therapy in patients with lupus nephritis (kidney disease).

“Lupus nephritis is one of the most common and dangerous complications of lupus,” commented Kenneth M. Farber, President and CEO of the Lupus Research Alliance. “These positive results suggest that voclosporin plus standard of care may provide the first safe and effective treatment option for the many people with lupus nephritis. It is especially gratifying to see the robust patient participation in this trial. Involving the community in clinical research has long been a focus of the LRA and our affiliate Lupus Therapeutics, the only organization focused solely on conducting lupus clinical trials throughout North America.”

Lupus Therapeutics is currently working on two clinical trials in lupus nephritis – the PAISLEY study testing the safety and effectiveness of BMS-986165 as a potential treatment and the DIVINE study which recently reported preliminary results towards the goal of utilizing multiple imaging techniques to enable non-invasive monitoring of kidney function. In addition to continued advancement of fundamental research of lupus nephritis, the Lupus Research Alliance is also working to address its diagnosis and management through our collaboration with the National Kidney Foundation on the recently released Continuing Medical Education program for healthcare providers.

From the Lupus Research Alliance, the world’s leading authority in lupus research.

Dear David,

Tired of the hustle and bustle of the holiday season? Well, you can do something about it right now.

Start celebrating by taking stock of what truly matters:
HOPE & INSPIRATION — two qualities you have in abundance.

Give back today — GIVING TUESDAY — by making a truly meaningful gift to the Lupus Research Alliance. This gift is guaranteed not to be overlooked or forgotten. It may be part of the next big BREAKTHROUGH in lupus research!

So, forget Black Friday steals, Cyber Monday savings, and all those secret sales alerts in your inbox — and celebrate generosity that can bring hope to the world.

This GIVING TUESDAY celebrate hope. This GIVING TUESDAY celebrate promising research that could lead to a cure.

As the father of a daughter with lupus, I can’t think of a more joyful holiday gift!

Sincerely,

Joe Mauriello
Member of the Board

P.S. Don’t start the season without standing behind the Lupus Research Alliance once more! In addition to your gift, you can help grow the community of lupus supporters.

It’s easy to do. Just Forward this email … like us on Facebook … share our Tweets … and post on Instagram. Use #Breakingthrough to show you’re on our team.

Remember: 100% of your gift will directly support critical lupus research programs!

The Lupus Research Alliance is the world’s leading authority in lupus research.

16TH ANNUAL LUPUS MEETING AND
ADVOCATE FOR LUPUS RESEARCH DAY

March 9-10, 2020
Washington, DC

Lupus patients still only have one therapy specifically developed for lupus, and other treatment options often cause serious side effects. Yet, federal funding for lupus research at the U.S. National Institutes of Health is significantly lower than it was 10 years ago.

Join the Lupus Research Alliance on The Hill to tell your Representatives and Senators why more funding for lupus research is critical!

Every March for more than 15 years, the Lupus Research Alliance has hosted a two-day Annual Lupus Meeting and Advocate for Lupus Research Day in Washington.

On Monday, March 9, you will learn the issues and how to convey them effectively. On Tuesday, March 10, you will meet with members of Congress and/or their staff to share your personal story and present the case for more lupus research dollars.

Spots are limited, so register now to reserve yours!

From the Lupus Research Alliance, the world’s leading authority in lupus research.

Dear David,

What a tremendous year we had … and all thanks to you!

Throughout our history, Lupus Research Alliance has continued to dramatically change so much about what the lupus community knew about this disease—and 2019 was no exception.

Improving the lives of those affected by lupus through medical research was our aim—and the year was filled with many successes.

Take a look! This link offers just a glimpse of our many breakthroughs in 2019. How did we do it? The answer, quite simply, is you!

Loyal donors like you enabled us to help some of the world’s most brilliant scientists bring their ideas for tackling lupus to fruition.

As the father of a daughter with lupus—and as a board member of this amazing organization—you have my heartfelt gratitude.

So, before this year slips away from us, I urge you to make one final gift to the Lupus Research Alliance before December 31^st. And stick with us in 2020! Together, we’ll beat lupus for good!

This Holiday Season give the gift of hope … hope that the cure for lupus will be discovered.

Sincerely,

Joe Mauriello
Member of the Board

P.S. Take full advantage of a tax break for 2019! Make your year-end gift to the Lupus Research Alliance today. And remember, 100% of your contribution directly supports lupus research programs.

If you recently made a gift — THANK YOU very much!

The Lupus Research Alliance is the world’s leading authority in lupus research.

Congress Set to Double Funds for Lupus Research - THANKS TO LRA ADVOCATES

Lupus Research Alliance advocates have good reason to pat themselves on the back today! The 2020 Defense Appropriations Act, on which Congress will vote in the coming days, would provide exactly what in-person and virtual advocates requested during “The Lupus Research Alliance 15^th Annual Advocate for Lupus Research Hill Day” in March.

The new spending bill would double the existing budget to $10 million for the Department of Defense Lupus Research Program and provide a $3 billion increase to the National Institutes of Health, bringing that total to $41.6 billion for biomedical research.

LRA President and CEO Kenneth M. Farber commented, “With this budget increase, twice as many grants for promising research can be awarded. That means twice the potential for a discovery that can deliver new therapies and a cure.”

The Lupus Research Alliance is the world’s leading authority in lupus research.

New Phase 3 Study Shows Positive Results for Benlysta® in Lupus Nephritis

The Lupus Research Alliance is thrilled to share exciting news from GSK that Benlysta® (belimumab) demonstrated positive clinical trial results in treating lupus nephritis (LN), a common and dangerous complication of lupus causing inflammation of the kidneys. Called BLISS-LN, this Phase 3 trial is the largest ever conducted among patients with lupus nephritis and paves the way for a new treatment for the disease. Belimumab is already approved by the U.S. FDA to treat systemic lupus erythematosus (SLE).

The company expects to submit data to the FDA in the first half of 2020 to seek approval of the drug as a treatment for lupus nephritis.

Kenneth M. Farber, President and CEO of the Lupus Research Alliance said: “We are very gratified that at long last additional treatment options are emerging for lupus nephritis. Belimumab is the only drug specifically developed and approved for lupus in decades, and the fact that it has shown benefit, not only for generalized SLE, but also now for lupus nephritis, is great news. GSK has long been a terrific partner to the Lupus Research Alliance, and we extend our congratulations as well as appreciation to GSK, to the investigators who enrolled patients in the study, and especially to the people with lupus who generously participated.”

Phase 3 studies test the drug in a large group of patients with a randomized, double-blinded trial design, which means people are randomly selected to receive either the drug being tested or placebo, and no one knows who received what until the end of the study. Phase 3 studies compare the new treatment plus standard of care (the treatment most accepted in medical practice) versus placebo plus standard of care.

“We encourage people with lupus and their families to visit our website LupusTrials.org and learn about clinical research. Talk to your doctor and see if there’s a study that’s right for you. Your participation is critical – we can’t deliver new treatments without your help,” ended Ken Farber.

The Lupus Research Alliance is the world’s leading authority in lupus research.

Positive Results on Anifrolumab for Lupus Published in New England Journal of Medicine

The good news just keeps coming, so we’re emailing you again to share the excitement!

We are delighted to report positive results published today in the online edition of New England Journal of Medicine from AstraZeneca’s Phase 3 TULIP-2 trial. This late-stage randomized trial studied the investigational biologic anifrolumab as a potential treatment for systemic lupus erythematosus (SLE or lupus).

The new report provides more details showing that anifrolumab, which targets type I interferon, met its primary endpoint to significantly lessen disease activity. Of those treated with anifrolumab, nearly 48 percent responded to treatment compared with 32 percent of those given a placebo.

Our President and CEO Ken Farber commented, “We are finally seeing a light at the end of the tunnel in lupus with this and other Phase 3 trials bringing us closer to much-needed new therapies. The LRA is particularly proud to see decades of work by our funded scientists on understanding the type I interferon pathway lead to the development of anifrolumab as a potential new treatment.”

The Journal featured an accompanying editorial by long-time LRA Scientific Advisory Board member Dr. Jane Salmon, Hospital for Special Surgery and LRA-funded investigator and reviewer Dr. Timothy Niewold, NYU Langone Health.

The Lupus Research Alliance is the world’s leading authority in lupus research.

Dear David,

It’s impossible to adequately thank you!

Tremendous supporters like you enable the Lupus Research Alliance (LRA) to uncompromisingly focus on stopping lupus in its tracks and improving how people fare with treatment.

Your support empowers us with the means to ask bold questions, engage the world’s best and brightest scientists, and pursue the most promising avenues of lupus research.

Can we count on you once more?

Please make your year-end, tax-deductible gift to the LRA now. Donate today and you’ll be able to take full advantage of the tax deduction you’ll receive for 2019.

If you recently sent your year-end contribution, please accept my sincere gratitude.

Sincerely,

Joe Mauriello
Member of the Board

P.S. I hope your commitment to the LRA remains as steadfast as ever because there is so much great research planned for 2020! And allow me to remind you that 100% of your gift will directly support critical lupus research programs! .

If you recently made a gift — THANK YOU very much!

The Lupus Research Alliance is the world’s leading authority in lupus research.

Have Fun, Do Good, and Play for a SUPER Prize!

Are you Ready for the Playoffs?!?!

Bet on the Lupus Research Alliance to Win a Trip to
Super Bowl LIV!

Help us tackle lupus -- play the Saturday, January 4th Playoff Games in this week's FanDuel Duel for Difference (only games on January 4 are eligible for the contest and to benefit the Lupus Research Alliance)!

First place will win the highly sought-after Grand Prize – Two tickets and hotel accommodations at Super Bowl LIV in Miami.

Use this dedicated link (www.fanduel.com/lupus) to play, and your entry fee will be donated to the Lupus Research Alliance.

Please share the link www.fanduel.com/lupus - with your friends, family, and co-workers on Facebook, Twitter and Instagram. The more people who Duel for a Difference, the greater difference we can make! Help us go on the offense and sack lupus!

Thanks for your support!

Sincerely,
Lupus Research Alliance

For more information or questions about this contest, please feel free to contact Jonathan Marks at jmarks@lupusresearch.org.

*FanDuel is the leader in one-day fantasy sports.

The Lupus Research Alliance is the world’s leading authority in lupus research.

Dear David,

I hope you will join me in celebrating the many unprecedented advances the Lupus Research Alliance (LRA) has made in 2019—incredible accomplishments highlighted in the enclosed issue of the Lupus Research Update (LRU) — thanks to your support.

First, let me extend my heartfelt gratitude to you for enabling us to fund pioneering new studies by 15 scientists with nearly $7.5 million in 2019! No other lupus organization has funded more groundbreaking projects in the last two decades than the LRA.

Because the work being conducted by Ignacio Sanz, MD, at Emory University School of Medicine has real potential to alter the course of lupus research … spark new treatments for the disease … and help doctors determine the best course of action for their patients, we selected Dr. Sanz as the winner of our 2019 Lupus Insight Prize.

All our investigators—and other major players in lupus research—had the chance to exchange ideas at the LRA’s 2019 annual Forum for Discovery scientific conference hosted in October.

Collaboration has always been a hallmark trait of the LRA—and this idea-sharing and merging efforts is not just limited to our scientists. You, too, are a major contributor. The LRA is the world’s leading private funder in lupus research and we have you to thank for that distinction!

So, please help the LRA have another stellar year of breakthroughs. Make your most generous tax-deductible year-end gift today. Together, we can accelerate the pace of discovery in 2020!

And remember that our Board of Directors has pledged to underwrite all fundraising and administrative costs so that 100% of your donation will go directly to research programs.

We wish you a happy and healthy 2020.

Gratefully,

Ken M. Farber
President and CEO

P.S. For all of our recent groundbreaking advances, we still need you to keep the momentum going. Your tax-deductible gift today will help us underwrite more scientific research—like the truly remarkable work described in this 2019 issue of the Lupus Research Update.

The Lupus Research Alliance is the world’s leading authority in lupus research.

Dear David,

Here’s a suggestion for the perfect New Year’s resolution—and it’s one you can keep! Commit yourself once more to the Lupus Research Alliance (LRA) and make your gift right now.

Don’t delay. Act now and you’ll receive your full tax-deduction benefit for 2019.

I’m so pleased to be able to tell you that my fellow board members and I are underwriting all fundraising and administrative costs. This means that 100% of your year-end donation will go directly to lupus research programs.

You give me hope. Your generosity helps the LRA focus our attention on developing new lifesaving therapies for ever greater numbers of people with lupus—and pursuing new opportunities to discover a cure.

Take a moment to make your year-end, tax-deductible contribution now!

Wishing you and your family a Happy New Year!

Joe Mauriello
Member of the Board

P.S. December 31st is fast approaching. Please make your gift now. If your gift and this email crossed each other, please accept my sincerest gratitude for your generosity.

The Lupus Research Alliance is the world’s leading authority in lupus research.

Dear David,

Thank you! Your support in 2019 allowed the Lupus Research Alliance (LRA) to maintain a standard of excellence in virtually every area of lupus scientific inquiry that is second to none.

In fact, when I think of the LRA’s greatest strengths, I think of you!

So, as 2020 begins, I want you to know—as the father of a daughter with lupus and an LRA board member—that you are helping us to know more about this disease than was ever imagined!

My wish for you is that the entire year brings you happiness, health, and prosperity.

Joe Mauriello
Member of the Board

P.S. Stay tuned and connected in 2020! The LRA has more great investigations in store and I’ll be happy to tell you about them. And keep giving as generously as you have! You’re helping us make a difference in lupus research.

The Lupus Research Alliance is the world’s leading authority
in lupus research.

Share LRA’s Excitement About What Lies Ahead for Lupus Nephritis in 2020

2020 promises to be an exciting year in lupus, and lupus nephritis in particular! We expect to see significant progress in new drug development with anticipated submissions for FDA approval and many opportunities to join late-stage studies exploring other potential treatments!

Up to half of people with lupus will have lupus nephritis – damage to the kidneys that affects the ability to clear the body of wastes and toxins.

LRA is Uncovering What Causes Lupus Nephritis to Further Improve Treatment

The Lupus Research Alliance has invested millions in research to get us to the point we’re at with potential new treatments for LN. And we continue to invest in promising projects to improve how this serious complication is diagnosed, monitored and treated. Right now, we are funding ten scientists to focus on this dangerous complication of lupus, and the pay-off could be huge. With your help, we can fund more in the coming year!

Have You Thought About a Clinical Trial as a Treatment Option?

With so few current treatment options for lupus and lupus nephritis, patients may benefit from joining a clinical study. Right now, five national trials are testing interventions for lupus nephritis that you may be able to join. To learn more about these, as well as over 150 other trials for lupus and its many manifestations, visit LupusTrials.org, LRA’s website dedicated to information about clinical studies. Then talk to your healthcare provider about which may be right for you.

The Lupus Research Alliance is the world’s leading authority
in lupus research.

LRA Leading Exploration of the Microbiome
as a New Frontier in Lupus

The microbiome is a hot area for exploration in many diseases – and here is our own Dr. Teodora Staeva to explain how it is a new frontier for lupus. Trillions of bacteria and other microorganisms work well together inside our bodies, but in people with lupus these microbes may trigger autoimmune attacks.

Read more for details on the trailblazing work the LRA is funding to understand the role of the microbiome in lupus and how altering it may offer a new treatment approach.

LRA-Funded Scientist Finds Way to Keep
T Cells from Running Amok

T cells are immune cells that play an important role in fighting foreign pathogens, like viruses and bacteria, but some T cells can trigger damage in lupus if not regulated and allowed to run amok. A study led by Dr. Randolph Noelle, recipient of LRA’s Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity discovered that a protein VISTA can keep the T cells in line. These new results support development of potential treatments that could turn on VISTA to prevent the immune system from attacking patients’ tissues.

LRA Meets Every Criteria for Accreditation by
Better Business Bureau’s Charity

The Lupus Research Alliance is proud to be the only national lupus organization to have met 20 out of 20 Standards for Charity Accountability by the National Better Business Bureau Wise Giving Alliance (BBB WGA). This non-profit “helps donors make informed giving decisions and promotes high standards of conduct among organizations that solicit contributions from the public.”

Watch our Executive Director Andrea O’Neill chat with President and CEO of BBB Wise Giving Alliance H. Art Taylor about our mission and goals.

From the Lupus Research Alliance, the world’s leading authority
in lupus research.

LRA Celebrates Major Research Breakthroughs in 2019

2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science fronts. The Lupus Research Alliance (LRA) is incredibly proud that every new discovery leading to a brand new medicine for lupus had its origin in work funded by LRA years ago.

The past 12 months delivered many exciting “firsts” for lupus -- three positive Phase III clinical trials, Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration including one in lupus nephritis (a serious form of lupus affecting the kidneys), and the first treatment approved for pediatric lupus, among other developments.

Watch this video to hear the highlights from LRA President & CEO Kenneth Farber, while Chief Scientific Officer Dr. Teodora Staeva describes other major breakthroughs in basic research science supported by the LRA. Discoveries included fascinating work on the gut microbiome and novel research on biomarkers or molecules that could be detected in the urine, skin and blood that could minimize invasive kidney biopsies. These and other research efforts are advancing understanding of lupus and will help pave the way for future treatments and drive us closer to a cure.

The LRA celebrates this year’s achievements and looks forward to continued positive developments in 2020. Read More.

The Lupus Research Alliance is the world’s leading authority
in lupus research.

LRA Launches Largest-Ever Team Grants to
Unravel Lupus Complexity

The complexity of lupus has been a challenge for decades, but advances in human immunology, technology, and computation offer an unprecedented opportunity for accelerating major advances. The time is right to bring personalized medicine to lupus treatment. And going into 2020, the Lupus Research Alliance is seizing that opportunity.

It starts with collaboration – and the Lupus Research Alliance is issuing a new grant program that calls on the best minds in different areas of research to work together in multi-disciplinary teams. Called the Global Team Science Award, the new funding program will provide up to $3 million over three years – the largest lupus research grants ever given by any non-governmental, not-for-profit institution.

“There is real wisdom to the old saying – the sum is greater than its parts,” commented LRA Chief Scientific Officer Dr. Teodora Staeva. “An all hands-on-deck approach is critical to unravel lupus. This Award provides the resources to assemble the talent and the tools to tackle lupus from many angles.”

As the catalyst for collaboration, we are proud to lead the world’s scientists to transform lupus treatment and drive to a cure.

From the Lupus Research Alliance, the world’s leading authority
in lupus research.

We Need Your Voice!

Advocate With Us March 9-10, 2020 in DC

Don’t miss your chance to represent the lupus community on The Hill to tell Congress why more funding for lupus research is critical! Join us at our 16^th Annual Lupus Meeting and Advocate for Lupus Research Day.

Registration closes on January 31st, so register now!

This year, we will explain why research funding is so vital in a briefing for Congress as well as individual visits. We need every advocate to share their lupus story so legislators understand what the complexity of lupus really means and what more research can achieve.

An intimate, inspirational and impactful meeting, these two days can make a difference not only in the lives of our nation’s leaders, but perhaps even in your own…

As one past participant described: “It was an exhilarating day! We enlightened some and enticed them to learn more. If they could only see their expression when they start to imagine what it’s really like to live with lupus!”

Share this empowering experience. Don't miss the January 31^st deadline!

From the Lupus Research Alliance, the world’s leading authority
in lupus research.

Dear New York Tri-State Lupus Community,

Are you...
…currently being treated for lupus and have a lupus-related emergency you can’t afford?
…living with lupus in the Tri-State area in the eligible counties above?
…age 18 or older diagnosed with lupus or the parent/guardian of a child diagnosed with lupus?

If you answered “yes” to all of these questions, you may qualify for help through the PA Fund for Patient Advocacy Lupus Emergency Grant Pilot Program.

As background, the PA Fund’s mission is to make a difference in the lives of people with lupus and their families through advocacy and care. We are committed to supporting people who have lupus through our Lupus Emergency Grant Program (LEGP). Offered as a pilot to start in the New York Tri-State area, LEGP aims to help relieve immediate financial concerns of people with lupus who are struggling to handle emergency living expenses due to illness.

If you or a loved one have lupus and want to learn more about LEGP, please click here for information about the program, eligibility requirements and the grant application. Or email the PA Fund at legp@lupusresearch.org. Please note, to apply applicants must show financial need, and grants must be directly related to lupus treatment or a lupus-related emergency.

The program will end twelve months from the start date or when the allocated funds have been distributed, whichever is sooner. If you are in financial need because of lupus, please know you are not alone! We are here to help.

Best regards,

Patti Allen
Founder and Director
PA Fund c/o Lupus Research Alliance

The Lupus Research Alliance is the world’s leading authority
in lupus research.

Think with Your Heart: Gift-Forward a Priceless Legacy for Lupus on National Organ Donor Day

In recognition of National Organ Donor Day, the Lupus Research Alliance (LRA) is launching a new campaign to encourage people with lupus to think with their hearts to help scientists solve how and why lupus can impact the brain. To address brain-related issues, the LRA has partnered with the Harvard Brain Tissue Resource Center to create the first-ever Lupus Brain Bank and together ask people with lupus to gift-forward brain tissue to advance science for future generations.

Up to 95% of people with lupus experience neuropsychiatric lupus (NPSLE) which includes a wide range of symptoms such as not thinking clearly, forgetting things or in more serious cases, even seizures, strokes and psychosis.

Dr. Shayla Shorter, who oversees the new Lupus Brain Bank program and lives with lupus herself, has already signed up. “I am excited to take this powerful action in the fight against lupus. I took this first step for the next generation of people with lupus, and I hope others will too,” said Dr. Shorter.

It’s no accident that National Organ Donor Day falls on February 14. Have a Heart this Valentine’s Day and leave a priceless legacy to help reduce brain-related issues with lupus.

The Lupus Research Alliance is the world’s leading authority
in lupus research.

COVID-19 Caused Hydroxychloroquine Issues for Third of Lupus Patients, New Lupus Research Alliance Survey Finds

More than one third of people with lupus experienced significant issues filling their hydroxychloroquine (Plaquenil) prescription during the COVID-19 pandemic, according to results of a new survey conducted by the Lupus Research Alliance.

Representing 42 states, District of Columbia and Puerto Rico, survey respondents included 334 people with lupus who had already been taking hydroxychloroquine to manage symptoms related to lupus. Thank you to all who took part! We will relay our results to the FDA and other government agencies to help prevent this type of situation from happening again!

Watch Video of Webcast - Lupus and COVID-19: What You Need to Know

If you missed LRA's live webcast Lupus and COVID-19: What You Need to Know last week or just want a replay, click here for the video recording. Judging from the positive responses we received, we think you will find it informative and helpful in answering questions you may have had about research and other developments related to lupus and COVID-19.

We answered as many questions during the webcast as time allowed, but there were many more. We are regularly updating our website, including the Learn From Lupus section, with the latest information.

Learn Why Research Holds the Answers

Graduate with honors - attend the fourth mini-class in our series on Lupus & COVID-19 by Dr. Shayla Shorter, LRA Scientific Program Manager. Click here to hear why research is the only answer to unraveling the complexity of disease, and how the LRA approaches and supports the entire process from basic research to clinical trials.

From the Lupus Research Alliance, the world's leading authority
in lupus research.

The LRA's Young Leaders Board hosted the Lupus & Cognitive Health webcast to answer common questions about cognitive issues and emotional health caused by lupus, particularly amid the COVID-19 pandemic. Watch the video recording of presentations by our four excellent panelists and moderated by Young Leaders Board member Martin Lewis.

Why People with Lupus Need to be More Careful in this Time of COVID-19

We've heard since Day 1 of the COVID-19 crisis that people with underlying conditions are at greatest risk for the coronavirus. But a recent paper in Clinical Immunology reporting on research related to work by Dr. Amr Sawalha that was funded by the Lupus Research Alliance outlines why those with lupus are especially vulnerable.

LRA-Funded Findings Suggest Way to Reverse Lupus Nephritis

A recently published study funded by the LRA explored how an unconventional treatment method now being tested for cancer could help lessen the severity of lupus nephritis (inflammation of the kidneys), a common and serious condition in people with lupus. This study was led by Dr. Joseph Craft and graduate student Dr. Ping-Min Chen at Yale University.

Promising results like these are made possible by your donations. Remember, every dollar you give goes directly to support lupus research programs because our generous Board of Directors covers all operating and fundraising costs. Help us unravel the complexity of lupus by supporting research and discovery to find new treatments and a cure!

From the Lupus Research Alliance, the world's leading authority
in lupus research.

Dear Friend,

The health of our lupus community is always our focus - funding the very best research to find better treatments and a cure. And that priority continues as people with lupus face particular challenges amidst the COVID-19 crisis.

Yet, there is real reason for hope even as we begin a Lupus Awareness Month amid a pandemic. As the world struggles to defeat the coronavirus, there is much that can be learned from the lupus community - people already living with a disease that requires extra safeguards against infection. We can also learn a lot from researchers already focusing on why the immune system malfunctions, and rheumatologists who battle the over-zealous immune response that characterizes autoimmune diseases like lupus.

To bring those lessons to the fore where lupus and COVID-19 intersect, we are launching a new campaign called Learn From Lupus. Around this theme, the Month will feature many opportunities for education, research updates and heightened lupus awareness including:

• Weekly video series, Mini-Classes with Shayla Shorter, Ph.D., LRA's Scientific Program Manager. Shayla obtained her doctorate in immunology from Emory University.
• Success Strategies the public can learn that people with lupus use to stay healthy.
• Virtual Brunch with Brenda on World Lupus Day / Mother's Day, May 10. Brenda is a broadcast journalist and dedicated member of the LRA Board.
• Lupus and COVID-19: What You Should Know, Part 2 webcast.

Unlike any before and hopefully any after, Lupus Awareness Month 2020 will make history. Let's use it as an unparalleled moment to celebrate the power of science, show your strength, and impart the many lessons you can share. As this inspiring video eloquently voices, when we come together with the full force of the lupus community, we can "not just survive, but thrive."

Warmest Wishes for Your Health and Safety,

Kenneth M. Farber
President & CEO
Lupus Research Alliance

From the Lupus Research Alliance, the world's leading authority
in lupus research.

You''re Invited to

LRA''s Family Night

Wednesday, August 26 at 7 PM EDT

Bring your kids to Family Night with GoGo squeeZ - and make delicious and nutritious cookies along with Chef Mom Autumn Rose Reo! Celebrate fundraising successes with outstanding Walk Team Captains and hear an insider preview of the first and largest virtual lupus Walk Event September 12.

Click here for the recipe so you can gather the ingredients and be ready to GoGo squeeZ Wednesday night!

Looking for a reason to smile? You won't be able to stop after watching this video preview of the ManyOne Can. eWalk with Us to Cure Lupus celebration September 12! And if you've walked with us in the past, you might just see your team.

From the Lupus Research Alliance, the world's leading authority
in lupus research.

New LRA-Supported Study Provides Clue to Potential
New Treatment Target

A new study supported by the Lupus Research Alliance discovered that molecules called type II interferons can trigger the immune system to over-produce the B cells that cause lupus inflammation. Type I interferons have already been shown to be very important in lupus which has led to exciting new medicines like anifrolumab now in clinical development for lupus.

Published in the Journal of Immunology, this new work led by Dr. Robert Caricchio shows that blocking another type of interferon (type II interferon) may be another great drug target.

Why People with Lupus Get Tell-Tale Rashes

A study led by LRA grantee Dr. J. Michelle Kahlenberg of the University of Michigan has revealed one reason why people with lupus tend to get tell-tale butterfly-shaped rashes on their faces as well as rashes on other body parts. Dr. Kahlenberg and her team found that certain immune system molecules produced by people with lupus help bacteria gain a foothold on the skin, where they can trigger inflammation. Her paper was published in the prestigious Journal of Investigative Dermatology.

Five Ways You Can Advance Lupus Research

We often hear people say, "I may have lupus, but lupus doesn't have me!" Here are five ways you can take action and feel more in control:

1. Consider a Clinical Trial - The more people engage in trials, the better scientists can understand the many types of lupus and explore drug development. Talk to your healthcare provider about taking part in a clinical study. Check out trials underway through the network managed by Lupus Therapeutics, wholly-owned affiliate and clinical trial arm of the Lupus Research Alliance.
2. Advocate - Visit your senators and representative when they are back home to ask Congress to budget more for medical research, and lupus specifically.
3. Stay Informed - Share your stories on our social media platforms Facebook, Instagram and Twitter.
4. Walk with Us to Cure Lupus - Join the thousands walking with the Lupus Research Alliance throughout the country to raise funds for the most innovative lupus research.
5. Give However You Can - Here are some fundraising ideas, and remember every dollar goes to LRA's research programs because our Board of Directors covers all operating and fundraising costs.

The Lupus Research Alliance is the world's leading authority
in lupus research.

Join our Next Webcast: Lupus and Cognitive Health

Presented by LRA's Young Leaders Board

People with lupus know only too well the need to avoid stress to prevent flares and optimize mental and emotional health. But that's pretty hard to do, especially in this time fraught with societal upheaval and amid a global pandemic that's significantly affecting members of this community more severely than most.

Our Young Leaders Board, a diverse group of young professionals, is presenting a webcast to address this very topic as part of LRA's Learn From Lupus program.

Speakers will share information about:

• Studies looking at reasons for cognitive impairment
• LRA research program to better understand what causes brain fog
• Advice on coping with mental health issues

LRA Congratulates AstraZeneca on Anifrolumab Data Shared at EULAR

The LRA is encouraged by positive data from two clinical trials on anifrolumab as a potential treatment for people with lupus presented by LRA grantee Dr. Eric Morand at the European League Against Rheumatism (EULAR) virtual meeting.

Anifrolumab is a novel investigational drug that blocks proteins produced by the immune system called type I interferons that promote inflammation - an area of research LRA investigators pioneered.

Your Advocacy Efforts Brought $10M to Lupus Research at the Department of Defense

The LRA is proud to share that the Department of Defense just announced Fiscal Year 2020 funding opportunities for the Lupus Research Program.

It was our advocates who convinced Congress to create this and maintain it with a $10 million budget this Fiscal Year.

We are urging the scientists we work with around the world to apply.

From the Lupus Research Alliance, the world's leading authority
in lupus research.

SAVE THE DATE

Monday, November 23^rd, 2020

7:00 PM EST

for

LRA''s Virtual Fundraising Event

Using the very latest technology, the Lupus Research Alliance will host an unparalleled virtual event featuring inspirational speakers, star-studded performances, surprise celebrity guests, and recognition of the extraordinary contributions by Jenny and Spencer Zwick of Solamere Capital and the LRA Board of Directors.

Together, we can help to fund new treatments and a cure
through the power of science.

Lupus Research Alliance Thanks FDA for Responsiveness to Plaquenil Shortage Concerns

Scientific Advisory Board Chairman Dr. Gary Koretzky, LRA President Kenneth Farber and LRA Chief Scientific Officer Dr. Teodora Staeva had a very productive discussion with the Food and Drug Administration (FDA) about the recent hydroxychloroquine|Plaquenil shortages that people with lupus have found amidst the COVID-19 pandemic. The FDA urged the LRA to remain in touch with the Agency as the situation continues to evolve.

"We urge people with lupus to answer our call for your experience so we can continue to keep the FDA apprised of the situation and request further assistance if needed," noted Mr. Farber.

Share your experience with the Plaquenil supply by participating in this brief survey by May 18.

How Does the Immune System Fight Invaders?

Dr. Shayla Shorter, Scientific Program Manager at the Lupus Research Alliance, is answering this question and many more in weekly video mini-classes throughout Lupus Awareness Month. Click here to watch the first of the series: How the Immune System Fights Back. "Graduate" the course by tuning in to all four sessions.

Celebrate World Lupus Day - Enjoy Brunch with Brenda

Grab a cup of coffee and tune in to Brunch with Brenda virtually this Sunday, May 10 at 1:00 PM EST- a doubly special pre-recorded celebration of World Lupus Day and Mother's Day as part of the LRA's Learn From Lupus campaign.

We''ll hear from broadcaster and LRA Board member Brenda Blackmon, her daughter, lupus warrior Kelly D. Kelly, and LRA's Executive Director Andrea O'Neill - three leading ladies of the lupus community.

The conversation will touch on major topics of concern including how to use telemedicine effectively and what LRA is doing to help educate the community and beyond. Join us for this informative and informal conversation shared in honor of World Lupus Day and Mother's Day!

From the Lupus Research Alliance, the world's leading authority
in lupus research.

Register for Live Webcast Hosted by LRA

• What parallels exist in the overreactive immune response we see in lupus and COVID-19?

• What insights can we gain from research in COVID-19 and lupus that can help improve treatment for both diseases?

• What's the bottom line about hydroxychloroquine?

The Lupus Research Alliance has taken several important steps to better understand these and other questions. Join this live webcast Thursday,
May 21 from 6:00 - 6:45 PM EST to hear from top experts about the latest research reports.

What Happens When the Immune System Overreacts?

Back for the second week is a fantastic mini-class by Dr. Shayla Shorter, Scientific Program Manager at the Lupus Research Alliance. Shayla is the science teacher everyone wished for - she makes it easy to understand and fun. Click here to watch the second of the four-part weekly series: What Happens When the Immune System Overreacts?

Please take our brief new survey by May 18 to share your experiences with Plaquenil supply during this pandemic! Our goal - to emphasize the consequences of shortages like this one to ensure people with lupus are never put in such a difficult situation again.

Preliminary results will be shared during our May 21 webcast. We will then compile and relay full survey results to the FDA. This specific attempt to collect information from the lupus community is entirely envisioned and driven by the LRA.

From the Lupus Research Alliance, the world's leading authority
in lupus research.

Register Now and Learn How You Can Contribute to the Lupus Treatments of the Future

Please join the Lupus Research Alliance and our affiliate Lupus Therapeutics for the interactive and informative Clinical Trials Virtual Fair on October 17, 10:00 am to 1:00 pm ET. You will hear about different types of clinical studies, what it is like to be in a clinical trial, how trials are being adapted in the face of COVID-19, and why your participation is so critical. You will also have the chance to chat with trial representatives about specific studies you might join.

And while you are learning more about how you make the difference in lupus trials, you will earn points for every activity. And points translate into awesome prizes!

Lady Gaga Recognizes Her Dad and the Lupus Research Alliance in New Book

All of us at the Lupus Research Alliance are so excited to read Lady Gaga's new book, Channel Kindness. Written with her mom Cynthia Germanotta and Born This Way Foundation reporters, the book shares stories of "Kindness and Community." We are honored to be referred to in the book as the organization "near and dear to my family" and the one her dad, Joe Germanotta, supports as a member of our Board of Directors. Thank you Lady Gaga for all you do to promote kindness and Congratulations!

In this time of unprecedented Amazon orders, visit smile.amazon.com and check off Lupus Research Alliance as the charitable organization you want to receive donations from eligible purchases.

From the Lupus Research Alliance, the world's leading authority
in lupus research.

LRA-funded Research Supports Two Drugs in Development

In a recent Lupus Research Alliance supported study published in Frontiers in Immunology, Dr. Ziaur Rahman linked molecules called TLR7 and type II interferon to impairing the ability of immune cells to do their job. These findings support further development by several companies of potential new lupus treatments that block these molecules.

Honoring Hispanic Heritage Month

Hear from one of our most active advocates, Juana Mata, about the risk of lupus among her Hispanic community.

As Juana notes, research shows that Hispanics are twice as likely to develop lupus than Caucasians. Many complications - particularly damage to the central nervous system like headaches, memory loss, confusion - are more severe among Hispanics, and more Hispanic women die of lupus than Caucasians. To help identify and develop urgently needed treatments that can prevent complications and stop the progression of the disease is exactly why the Lupus Research Alliance exists and persists.

From the Lupus Research Alliance, the world's leading authority
in lupus research.

Dear Lupus Research Advocate:

As you recall, in December the Lupus Research Alliance achieved a critical success in convincing Congress to double funding for the Lupus Research Program at the U.S. Department of Defense's Congressionally Directed Medical Research Program (CDMRP). The Lupus Research Program, along with others at the Centers for Disease Control and Prevention (CDC) and the Department of Health & Human Services (HHS), is investing vital resources to support research that could revolutionize the way lupus is treated, and one day cured.

BUT WE CANNOT REST ON PAST SUCCESSES!

Congress has begun its 2021 budget and appropriations process, and the Lupus Research Alliance is working with leaders of the bipartisan Congressional Lupus Caucus to continue pushing forward. The Lupus Caucus is currently circulating for signatures a letter to leadership of the Appropriations Committee requesting:

• $10 million for the DoD Lupus Research Program
• $10 million for the National Lupus Patient Registry at CDC
• $2 million for the HHS Office of Minority Health National Lupus Training Outreach & Clinical Trial Program.

WE NEED YOUR HELP!

The greater the number of Members of Congress who sign this letter, the greater the likelihood that lupus research remains a priority for the federal government. Please contact your Member of Congress TODAY and ask them to sign on the bipartisan Lupus Caucus letter led by Reps. Eddie Bernice Johnson (D-TX), Peter King (R-NY), and Bill Keating (D-MA). The deadline for signatures is March 10^th.

Your advocacy is critical to building a better world for lupus patients and their families.

The Lupus Research Alliance is the world's leading authority
in lupus research.

2020 Lupus Insight Prize Awarded to Dr. Jane Salmon for Improving the Health of Pregnant Women with Lupus and Antiphospholipid Syndrome

The Lupus Research Alliance is excited to award our 2020 Lupus Insight Prize to Jane Salmon, MD. The prize recognizes Dr. Salmon's discoveries related to the causes of complications among pregnant women with lupus and antiphospholipid syndrome (APS).

This funding will enable Dr. Salmon to develop a tool to identify patients with high-risk pregnancies and to test whether or not certolizumab, a drug used for rheumatoid arthritis, can reduce pregnancy complications in lupus patients with APS.

Potential Test to Monitor Lupus Disease Severity Supported by LRA Grant

With funding support from the LRA, Dr. Christian Lood has developed a new method to assess lupus disease severity. It relies on measuring immune complexes -- substances that form when antibodies recognize and attach to their particular target in the body. In lupus and other autoimmune diseases, these immune complexes can cause inflammation and organ damage.

Dr. Lood is now doing more experiments to see if this potential test can predict disease progression and organ damage in lupus. His goal is to use this test to identify those patients who might benefit from specific treatment options.

Don't Miss the Chance to Influence Lupus Clinical Trials

Please don't forget to fill out our survey by Sunday, August 9, so we can understand your perceptions of clinical trials and how COVID-19 may be impacting your routine medical care and clinical trial participation.

We plan to share survey results at our August 24 webcast on clinical trial innovation led by Lupus Therapeutics, LRA's clinical trial division. Details to come.

From the Lupus Research Alliance, the world's leading authority
in lupus research.

Lupus and COVID-19: What You Need to Know
Live Webcast

The Lupus Research Alliance (LRA) will host a live webcast for the lupus community to address the most frequently asked questions about COVID-19 in people with lupus, put the hydroxychloroquine shortage into perspective and highlight LRA actions on behalf of the community.

Join us on Thursday, April 2 at 6:00pm EDT/3:00pm PDT. Hear from an expert panel moderated by Brenda Blackmon, former news anchor and LRA board member, and including:

• Kenneth M. Farber - President and CEO, Lupus Research Alliance
• Daniel J. Wallace, M.D. - Associate Director, Rheumatology Fellowship Program, David Geffen School of Medicine Center, UCLA in affiliation with Attune Health & LRA Board of Directors
• Mary K. (Peggy) Crow, M.D. - Chief of Rheumatology, Hospital for Special Surgery & former Co-Chair, LRA Scientific Advisory Board

LRA-Funded Study Pinpoints a Key Player in Lupus Nephritis as Target for New Treatments

People with lupus often develop complications in major organs such as the kidneys, called Lupus Nephritis (LN). By taking pictures of the kidneys with a special microscope, Dr. Janos Peti-Peterdi's team found a chain of molecules that moves into the kidney, leading to LN. They also found that treating the kidneys with a protein called hyaluronidase was able to stop these molecules from entering the kidney, preserving kidney function.

This study opens the door to targeting these molecules to treat LN in the future.

Ensuring Minorities are Well-Represented in Lupus Clinical Research

People of color are two to three times at greater risk for lupus than Caucasians. But their participation is lower in clinical trials. It is essential that all groups are well-represented in trials to be sure that potential drugs are shown safe and effective among the people of greatest need.

Our own Diane Gross and Susan Erondu spoke at the National Minority Quality Forum annual meeting to share how the Lupus Research Alliance and our affiliate Lupus Therapeutics are addressing this disparity in trial representation. They were joined by Dr. Ashira Blazer of NYU School of Medicine who spoke about the science behind why lupus affects people of color more severely, and panel moderator Courtney Lang.

Don't Miss a Chance to Talk with Researchers Working on Lupus Clinical Trials!

In addition to learning from a panel discussion by top experts in lupus clinical research, you will be able to chat and ask questions with the people who are conducting lupus trials in major sites around the country.

From the Lupus Research Alliance, the world's leading authority
in lupus research.

HONORARY CHAIRS

Michael R. Bloomberg

Lady Gaga

Selena Gomez

CO-CHAIRS

Ira Akselrad
President
The Johnson Company

Richard K. DeScherer
Chief Legal and Compliance Officer
Bloomberg L.P.

Nadeem I. Maghji
Senior Managing Director in the Real Estate Group and Head of Real Estate America
Blackstone

Molly McCabe
Lupus Advocate

Robert W. Pittman
Chairman and CEO
iHeartMedia, Inc.

Julian Robertson
Chairman
Tiger Management

William J. Wolfe
Chairman
First Washington Realty, Inc.

HOST

Willie Geist
Host, Sunday Today with Willie Geist
Co-Host, Morning Joe

For more information, please contact Melissa at 212.376.5586 or mmundy@dsconsultinggroup.com

Dear Friend of the Lupus Research Alliance:

As you know, because of the possibility that Plaquenil (hydroxychloroquine) might be useful as a treatment for COVID-19, a serious shortage has developed which makes it very difficult for lupus patients who rely on this medicine to refill their prescriptions. While this shortage is more acute in some parts of the country than others, lupus patients everywhere are dealing with this problem.

The Lupus Research Alliance, along with many organizations in the rheumatology community, has worked very hard to alleviate this shortage and we are beginning to see some progress. A number of manufacturers have dramatically increased production, and additional product has begun to flow into the market. We have heard anecdotal reports that things are improving, albeit slowly. We will continue to monitor the situation closely.

It is unclear whether Plaquenil is an effective medicine for COVID-19. Many hospitalized COVID-19 patients are now given Plaquenil immediately upon admission and for at least an additional 4 days after that. Often, Plaquenil is given along with azithromycin, an antibiotic. Despite the lack of definitive proof that this regimen helps patients, it is prescribed for hospitalized patients because of anecdotal, but non-definitive, evidence that it works along with the excellent safety profile of Plaquenil. Plaquenil is sometimes being prescribed for COVID-19 patients recovering at home and is being hoarded as a medicine touted to prevent infection.

Within the next several days to several weeks, more reliable data about the efficacy of Plaquenil for COVID-19 may emerge. Nobody knows what this data will demonstrate. If Plaquenil proves to be of no value for COVID-19, demand will probably drop and the shortage will abate. If Plaquenil turns out to be beneficial for any aspect of COVID-19 infection or to help prevent COVID-19 infection, it is likely that demand will skyrocket. Right now, all we can do is speculate about what the data will ultimately show.

Here's what lupus patients need to know. If Plaquenil proves to be effective in treating or preventing COVID-19, it is possible, and perhaps likely, that serious shortages will confront lupus patients in the short and intermediate term. The Lupus Research Alliance will do everything possible to ensure that these shortages are resolved as quickly as possible, but the reality is that for some period of time, lupus patients may have real difficulty accessing this medicine.

We are bringing this to your attention now so that you will have time to develop a plan with your rheumatologist. We urge all patients to contact their health care provider in the near future to make decisions about what course of action to take in the event that Plaquenil becomes temporarily unavailable.

The good news is that alternative treatment strategies exist. Patients who control their lupus with Plaquenil and other medicines may find that those other medicines are adequate to prevent a flare. For patients who control their disease exclusively with Plaquenil, their rheumatologist might recommend a temporary switch to an alternative medicine until Plaquenil becomes available again. Because the risk of flare for patients who stop Plaquenil typically doesn't escalate for several weeks, rheumatologists might recommend that patients do nothing but watchful waiting for some period of time. The advice rheumatologists offer to each patient will be different, depending on the circumstances of that patient's experience with lupus. That's why it is important for lupus patients to discuss this with their physician to develop a plan tailored for them.

All of us hope that effective treatments for COVID-19 are discovered and that Plaquenil will continue to be available to lupus patients who have been taking it for years or even decades. Given the uncertainty, it is very important that lupus patients be prepared for any eventuality. The best way to do that is to contact your rheumatologist and make a plan as soon as possible. That way, if the Plaquenil shortage becomes worse, lupus patients will know the best course of action that they can take under difficult circumstances.

Please be assured that the Lupus Research Alliance will do everything possible to guarantee that any Plaquenil shortage is resolved as quickly as possible; we are working tirelessly on this issue. In the interim, call your rheumatologist, make a plan, and feel free to contact us if you have any questions.

Sincerely,

Ken

Kenneth M. Farber President, Lupus Research Alliance

Dear Friends,

Your well-being is the utmost priority for all of us at the Lupus Research Alliance (LRA). We are consulting with top lupus clinicians and scientists in monitoring the situation posed by the spread of the SARS coronavirus (SARS-CoV-2) often referred to as COVID-19, across the world and committed to doing everything we can on your behalf.

We listened to guidance from the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) and National Institutes of Health (NIH) and concerns from our own lupus community. People with lupus are considered immunocompromised, meaning at greater risk for infection both from the disease and certain treatments.

In accord with recommendations for people who are at greater risk to avoid travel and crowds as much as possible, we have cancelled all events through early May. We will continue to monitor policies from federal, state and local governments and update you about our special events and programs being postponed to future dates.

Using Technology to Keep Moving Forward:

• We postponed our March 9-10 Annual Lupus Meeting and Advocate for Lupus Research Day on Capitol Hill and in less than a week, turned it into a successful virtual event. The following day, lupus advocates reached out to legislators through our Legislative Action Center by email, social media and phone. The entire community can keep the momentum going by using the Legislative Action Center tools to continue to reach out to members of the Senate and House of Representatives. In addition, we have rescheduled the meeting and Congressional briefing for September 14-15. Stay tuned for more details.
• A meeting by Lupus Therapeutics, our wholly-owned affiliate, involving our LuCIN Clinical Investigators Network of top researchers from major academic centers and industry partners, was postponed from early April to December. We are committed to maintain the pace of research within the limitations the virus has imposed.

Meanwhile, the work of the Lupus Research Alliance keeps moving full steam ahead.

• Applications for LRA's competitive lupus research grants are continuing through a highly intensive review process.
• Our Scientific Advisory Board and expert reviewers are "meeting" via videoconference to evaluate the promise of each project to improve lives of people with lupus.
• We are extending the upcoming deadlines for our $1M Distinguished Innovator Award and our $3M Global Team Science Award to enable the submission of highly competitive proposals despite the unprecedented, unfolding global crisis.

LRA Employs Innovation in All Our Work

In addition to using the latest technology in our scientific research, we are using it in our daily work to find alternative ways to serve all of you. Our Operations and Finance Department is keeping the office running in every way, both physically and virtually. The lights are "on" and the doors are "open" even when we're not there.

Over the next couple of weeks every department will be reaching out with ways to stay informed and actively involved with the organization and your lupus community.

While we are all following recommendations to "socially distance" that doesn't mean isolation. We are here for you and we urge you to stay connected!

Here''s How:

• Visit our COVID-19 Frequently Asked Questions to learn more about the virus from the specific perspective of the lupus and autoimmune community. We are updating this regularly.
• Follow us on Facebook, Instagram and Twitter to keep up with the latest news about COVID-19 and developments in lupus research. And share information with others who look to you as a resource.
• Stay informed on lupus-related news by visiting our Newsroom for updates. We are continually updating our website with news that is of special interest for people with lupus.
• And, of course, the connections you've made with one another through the Community Forum on the LRA website remain present and strong.

The Lupus Research Alliance exists to improve the lives of people with lupus. We are not physicians and cannot offer medical advice and urge you to speak with your rheumatologist or caring physician about medical concerns. What we are is your best source of reliable information about science - the science of the disease and its treatment as well as the support in helping you understand issues that you may face - particularly during this challenging time.

Let's stay in close touch and take good care.

Sincerely,

Kenneth M. Farber

President & CEO Lupus Research Alliance

The Lupus Research Alliance is the world's leading authority
in lupus research.

Join Our Zoom Webcast

Redefining Lupus Clinical Trials Amid COVID-19 and Beyond

Monday, August 24 at 6 pm EDT

Ensuring the clinical trial process works for participants has always been the goal. But, COVID-19 has forced everyone to re-think how taking part in a trial can impact people with lupus and other high-risk groups.

Lupus Therapeutics, the clinical trial division of the Lupus Research Alliance, invites you to hear from a diverse, expert panel about why COVID-19 may just be the spark that empowers patients and drives innovation. Ask your questions and find out how people with lupus responded to our recent survey of your feelings about joining a clinical trial during COVID-19 and post-pandemic.

LRA-Supported Study Discovers How
Harmful Immune Cells Develop

In a new study published in the journal Immunity, Lupus Research Alliance-funded researcher Dr. Boris Reizis and his colleagues identified conditions under which immune cells called B cells begin to attack healthy genetic material (DNA). Dr. Reizis' findings highlight the potential of drugs in development such as anifrolumab and BIIB-059 may offer treatments to not only stop these attacks, but help prevent them from happening.

This work was made possible by the LRA's highly prestigious Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity which provides up to $1 million to allow each investigator to test promising approaches for potential new lupus treatments.

From the Lupus Research Alliance, the world's leading authority
in lupus research.

Join Our Live Webcast Tonight to Hear New Data on Lupus and COVID-19

It's not too late to register for tonight's live webcast with top lupus experts answering questions like these and more:

• What did we learn from the survey you, our lupus community, filled out about your experiences with hydroxychloroquine? Data will be shared for the first time.

• Are people with lupus more or less at risk for COVID-19?

• Are medications used by people with lupus more or less effective in COVID-19?

Find out tonight.

Are you still having trouble filling your prescription? Click here for information from the National Alliance of State Pharmacy Associations.

Learn Why Lupus Drugs May Work Against COVID-19

Don't miss the third mini-class in our four-part series by Dr. Shayla Shorter, Scientific Program Manager at the Lupus Research Alliance. Click here to hear Why Drugs for Lupus May Work Against COVID-19. In this easy-to-understand video, Professor Shorter will explain the different classes of drugs being considered, how they work and what we still need to learn.

From the Lupus Research Alliance, the world's leading authority
in lupus research.

More Exciting Lupus News from EULAR

EULAR, the e-Congress of the European League Against Rheumatism, went virtual this year to enable scientists from around the world to share their latest findings amid the COVID-19 pandemic. The LRA is pleased to share results from several clinical trials testing potential treatments for lupus and lupus nephritis including anifrolumab, belimumab, voclosporin, baricitinib, BIIB059 and NKTR-358.

It's Men's Health Month: Watch Martin Lewis's Inspiring Story

During June, Men's Health Month, we must remember that lupus does not just affect women - 10 percent of people with lupus are males of all ages and their symptoms can be more severe.

To recognize our male lupus community, LRA brings this inspirational video of actor Martin Lewis, who shares his experience of growing up with lupus nephritis and how talking with others helps him thrive.

New Guidelines from ACR For Lupus Care in COVID-19

The American College of Rheumatology enlisted 14 experts on infectious diseases and immune system illnesses to develop recommendations on treating lupus and related diseases amid the COVID-19 pandemic. The Lupus Research Alliance reports on these findings here from a paper published in Arthritis & Rheumatology. We recommend talking to your own healthcare provider before making any change to your medication regimen.

From the Lupus Research Alliance, the world's leading authority
in lupus research.

Our 2020 Forum for Discovery: Sharing the Latest News in LRA-Funded Research

The Lupus Research Alliance (LRA) held our annual scientific conference, the Forum for Discovery, online in true 2020 style. More than 150 funded investigators, scientific advisors, and partners from the pharmaceutical and biotech industries logged on from their computers around the world to hear about new discoveries from LRA-funded researchers.

The scientific program featured a keynote address from Mark M. Davis, PhD at Stanford University. Dr. Davis described a paradigm-shifting hypothesis that transforms our understanding of autoimmune diseases like lupus. Additionally, eight speakers shared their most recent discoveries from projects funded by the LRA. Discussion was lively and spurred new ideas for more exploration.

This year, our reporting from the American College of Rheumatology's annual meeting ACR Convergence 2020 meant watching presentations on our computers all day, every day for four days! Results of many clinical trials testing potential lupus treatments were highlighted.

The LRA is particularly proud to share results presented at the conference that were conducted, in part, through the Lupus Clinical Investigators Network (LuCIN) of Lupus Therapeutics, an affiliate of the LRA.

Click here for results of key studies of interest to our lupus community looking for new treatment options.

Differences Found in Genes Among African and European Americans Point to Possible Lupus Drug Targets

Lupus, like so many other diseases, affects people with African ancestry more severely than those with European ancestry. Those of African and European descent also respond to lupus drugs differently. Drs. Carl Langefeld, Peter Lipsky, and Kate Owen published a paper showing that some of these differences are due to groups of genes that vary between the two populations. They hope to pinpoint those groups of genes so researchers can use them to develop more personalized drugs.

This work was supported in part by a grant from the LRA as well as the Impact Award through the Lupus Research Program (LRP) within the Department of Defense - a program the LRA advocated to create - and the NIH. It is particularly timely to report these results in recognition of Veteran's Day, tomorrow, November 11!

From the Lupus Research Alliance, the world's leading authority
in lupus research.

LRA Applauds Aurinia on Priority Review of Voclosporin by U.S. FDA for Lupus Nephritis

We are pleased to share great news that the U.S. Food and Drug Administration accepted the New Drug Application and granted priority review designation to Aurinia Pharmaceuticals Inc. for its investigational drug voclosporin as a treatment for lupus nephritis - inflammation of the kidneys.

"If approved by the FDA, voclosporin would be the first treatment approved specifically for this devastating complication that affects up to half of the five million people worldwide with lupus," noted Lupus Research Alliance President and CEO Kenneth M. Farber. "Lupus nephritis can cause irreparable damage to the kidneys that requires dialysis or an organ transplant. A new treatment for lupus nephritis could dramatically change the lives of people with lupus."

Under priority review designation, the FDA sets a goal to review and act upon the application within six months; in contrast, standard review can take ten months. Aurinia anticipates having a decision from the FDA by early 2021. We will keep you posted!

From the Lupus Research Alliance, the world's leading authority
in lupus research.

Happy World Lupus Day - Join Us for Brunch with Brenda

It's 1:00 PM ET -- time to tune in to Brunch with Brenda for World Lupus Day and Mother's Day, or watch any day you wish!

As part of our Learn From Lupus campaign, we''ll hear from broadcaster and LRA Board member Brenda Blackmon, her daughter, lupus warrior Kelly D. Kelly, and LRA's Executive Director Andrea O'Neill.

Their conversation shares lessons the world can learn from people with lupus and concerns we've been hearing from many of you on social media, emails and phone calls. Brenda, Kelly and Andrea touch on issues people are voicing including the use of telemedicine - so watch for tips on how to make the most of your doctor "visits."

Key takeaway from Brenda: "Pace yourself, have patience, always have hope and never forget that Mother Knows Best!"

From the Lupus Research Alliance, the world's leading authority
in lupus research.

Dear Friends,

As we start Week 2 of our "new normal" with the coronavirus pandemic, the Lupus Research Alliance continues to watch rapidly changing developments regarding COVID-19 closely. We are working on your behalf with the federal government and healthcare agencies, and we promise to bring you important and relevant updates.

First of all, your safety is our biggest concern. Living with lupus, you are already a pro at doing what you can to avoid contact with people who are sick. Now's the time to double-up on your usual precautions and follow the recommendations of the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) by washing hands often for at least 20 seconds, keeping at least six feet away from others, avoiding crowds, and if you or others around you are sick, wearing a mask. Please visit our FAQ for more information.

Thrust into the spotlight this week was news about the potential benefit of anti-malarial drugs hydroxychloroquine (brand name Plaquenil) and chloroquine in treating COVID-19. As you know, Plaquenil is the most commonly used drug for lupus. Anecdotal evidence from small studies suggests that these drugs may reduce symptoms of COVID-19 and even slow down replication of the virus. Even though these drugs are not officially approved by the U.S. Food and Drug Administration for the treatment of COVID-19, physicians are using Plaquenil on an "off-label" basis in patients with COVID-19.

Given this extraordinary development, shortages of Plaquenil are developing. In some pharmacies, especially in New York and California, the drug has been unavailable. Although it is unclear how pervasive shortages might become, the Lupus Research Alliance and other organizations in rheumatology have urged the U.S. Food and Drug Administration to address the shortages and in the past few days we have seen some good news:

• The World Health Organization announced a global "Solidarity Trial" to test which drugs, including chloroquine, may be most effective against the virus.
• The U.S. Food and Drug Administration responded to pleas from the Lupus Research Alliance and other organizations as well as the White House with an encouraging statement from FDA Commissioner Stephen Hahn, M.D. underscoring that the FDA is working quickly to enable the rapid testing of hydroxychloroquine in patients with COVID-19 while engaging with U.S. manufacturers to ramp up its production to mitigate potential shortages. Dr. Hahn added, "We will take all steps to ensure chloroquine remains available for patients who take it to treat severe and life-threatening illnesses such as lupus."

Literally overnight, the pharmaceutical industry responded with important donations to ensure adequate supply:

• Novartis committed to donate up to 130 million doses of hydroxychloroquine by end of May and is supporting ongoing clinical trial efforts to evaluate hydroxychloroquine and chloroquine in treating COVID-19. The company is also exploring scaling up its ability to increase supply to ensure patients currently depending on this medicine are not impacted by the situation.
• Mylan N.V. started producing hydroxychloroquine tablets at its U.S. manufacturing facility and initiated production outside of the U.S. The company expects to ramp up manufacturing to provide 50 million tablets by mid-April.
• Similarly, Teva said production is ramping up and that it will donate 6+ million doses of hydroxychloroquine sulfate tablets to hospitals across the U.S.
• Bayer announced it is joining the U.S. government to fight against COVID-19 with a donation of 3 million tablets of their malaria drug Resochin, the brand name for chloroquine phosphate. Currently, Resochin is not approved for use in the U.S. but Bayer is working with appropriate agencies to secure an Emergency Use Authorization for the drug's use in the U.S.

The Lupus Research Alliance will continue to monitor the situation closely to ensure shortages abate in the future.

Several other companies announced the start of clinical trials on existing rheumatoid arthritis drugs to test their safety and effectiveness in COVID-19:

• Genentech announced it received approval from the FDA to initiate a Phase III trial to assess its marketed drug Actemra? (tocilizumab) as a treatment for adults with severe COVID-19 pneumonia.
• Regeneron Pharmaceuticals, Inc. and Sanofi also announced it had initiated clinical trials of their Kevzara? (sarilumab) for the treatment for severe symptoms of COVID-19.

It is our hope that these measures and others will ensure that lupus patients are able to continue with their regular therapies. We at the Lupus Research Alliance will continue to push for access to the medications you need. As with all medication concerns, please speak with your rheumatologist or caring physician.

I'd like to end on a personal note. This is undoubtedly a stressful time. Practicing self-care and keeping positive is critical right now. Our Chief Administrative Officer Debra Rose has been sharing daily uplifting quotes to keep our staff positive. One of my favorites is:

"Helping others, encouraging others, are often acts of being kind that have more meaning than you may realize." Catherine Pulsifer

Another way to gain inspiration and give hope to others is to visit our Community Forum.

The coming weeks are sure to bring other developments. We will do everything we can to bring you the latest news and advocate for our lupus community. Meanwhile, take good care, stay calm -- and stay healthy!

Sincerely,

Kenneth M. Farber

President & CEO Lupus Research Alliance

The Lupus Research Alliance is the world's leading authority
in lupus research.

Dear David Campbell,

Let's face it. We are living in a new, challenging reality.

COVID-19 requires all of us to stand by our families . and stand in unity to support important work we believe in-like the critical, lifesaving research that your gifts to the Lupus Research Alliance (LRA) support.

Before I tell you about Giving Tuesday Now, I want to take this opportunity to express my gratitude to you for everything you do to make lupus a disease of the past!

Great donors like you propel the world's most pioneering lupus research!

I'm committed to not let COVID-19 interfere with the extraordinary success the LRA has had in changing the very landscape of lupus research-and I hope you will join me. We have been through challenging times before-and donors at the level of support you have demonstrated incredible loyalty time and again to funding the world's most promising lupus research!

Participate in Giving Tuesday Now-at any level of your choosing-and be part of the next big breakthrough in lupus research.

Sincerely,

Brenda Blackmon
Member of the Board

From the Lupus Research Alliance, the world's leading authority
in lupus research.

In the midst of this difficult time, we're pleased to share some positive news for the lupus community on the research front:

New Awardees Announced by the Lupus Research Program Advocates Helped Create

Thirteen new applications for promising scientific studies were just recommended for funding through the Lupus Research Program within the Department of Defense. This would not have been possible without the work of you, the advocates who represented the Lupus Research Alliance in our outreach to federal legislators in Washington, DC.

The $5 million in awards for Fiscal Year 2019 brings the total to $15 million over three years.

Aurinia Moves Voclosporin Closer to Potential FDA Approval for Lupus Nephritis

The Lupus Research Alliance is pleased to share news from Aurinia Pharmaceuticals that moves its potential treatment for lupus nephritis, voclosporin, one step closer to approval by the U.S. Food and Drug Administration (FDA). The Company recently announced that it has started a Rolling Submission of its New Drug Application to the FDA.

This means that Aurinia can submit portions of the data provided in the New Drug Application in stages, and the FDA can review as it is available rather than waiting to review until the entire application is complete. This can significantly speed up the process of review and potential approval of voclosporin as a treatment for lupus nephritis.

Iguratimod May Offer Alternative Therapy for Resistant Lupus Nephritis

An investigational treatment, iguratimod showed positive results in an early clinical study conducted in China of people with lupus nephritis that is refractory, meaning it has stubbornly resisted previous treatment with at least two immunosuppressants.

Iguratimod is approved for treating rheumatoid arthritis, another autoimmune disease, in northeast Asia. This trial was based on an earlier study of mice with lupus where iguratimod prevented nephritis, lowered the amount of protein in the urine and reduced inflammation in the kidneys.

Lupus and COVID-19: What You Need to Know Live Webcast

Moderated by newscaster and LRA Board member Brenda Blackmon, our April 2^nd live webcast brought our president and CEO Ken Farber along with two renowned lupus experts Dr. Daniel Wallace and Dr. Peggy Crow to answer the most frequently asked questions we've been hearing from all of you. If you were unable to join us for the webcast, watch the full video here.

From the Lupus Research Alliance, the world's leading authority
in lupus research.

Lupus Drug Hydroxychloroquine in Testing for COVID-19

Currently there is no drug specifically designed to treat COVID-19. However, researchers across the globe are working hard to find options for new therapies. Two drugs originally developed for malaria, chloroquine and hydroxychloroquine -- now a commonly used lupus drug -- are looking promising in studies.

In lab tests, scientists have found that chloroquine can block the SARS-COV-2 virus that causes COVID-19 from entering cells. Clinicians then tested the chloroquine treatment in patients and found that among 100 COVID-19 patients, those given chloroquine recovered faster and had less severe symptoms than those who did not receive the drug.

Hydroxychloroquine (Plaquenil) is very similar to chloroquine, and in the lab, scientists have found that it may work even better in preventing SARS-COV-2 infection of cells.

What could this mean for people with lupus?

While the original study of 100 patients is encouraging, scientists do not yet know if Plaquenil can treat COVID-19. It is also unknown if people taking Plaquenil for conditions such as lupus will be protected from the virus. Scientists are doing lab experiments and clinical trials to investigate these types of questions. They are also looking at other drugs as potential treatment options.

Research is moving very quickly. The World Health Organization announced yesterday a global "Solidarity Trial" to test which drugs may be most effective against the virus. We will keep you updated on this and other developments in the research fight against COVID-19.

The Lupus Research Alliance is the world's leading authority
in lupus research.

New Study Funded by LRA Sheds Light on Potential Treatment Approach that May Reduce Antibodies that Cause Lupus

An exciting new study funded by an LRA grant to Dr. Theresa Lu identifies a potential treatment approach that could reduce the main culprit behind lupus -- destructive antibodies -- that attack healthy tissues and organs instead of protecting them from outside invaders.

The results, published in Science Immunology, shed light on an approach that could limit the number of antibody-forming cells and lessen their role in causing autoimmunity.

Three Leading Healthcare Organizations Issue Statement on FDA Action to End Emergency Authorization of Medications for COVID-19

The LRA is committed to bringing you important news about hydroxychloroquine as the world continues to Learn From Lupus.

Recently, a joint statement issued by three professional organizations including the American Medical Association stressed that the FDA's recalling approval of hydroxychloroquine for hospitalized COVID-19 patients does not apply to use of these medications for conditions like lupus.

LRA's Scientific Advisory Board Chair Dr. Gary Koretzky also urges lupus patients "to remember that rheumatologists suggest this medication because of its effectiveness in treating disease and its well-demonstrated safety profile."

One thing that has become crystal clear in this challenging time of COVID-19 is the incredible need and importance of biomedical research. The power of science can and will change lives! Please donate what you can to keep pushing the drive for new treatments and a cure at a fast pace.

From the Lupus Research Alliance, the world's leading authority
in lupus research.

Tell Congress Why More Funding for Lupus Research is Critical -
REACH OUT TODAY!

NOW is the time to speak up about more funding for lupus research! Join the Lupus Research Alliance (LRA) and advocates across the country as we raise our voices for lupus research.

LRA's funded researchers rely on grant funding from the National Institutes of Health and the Department of Defense''s Lupus Research Program to continue the work our investments allowed them to begin. And we need to ensure that the Food and Drug Administration has the resources needed to keep up with growing responsibilities around drug development.

Please use our Legislative Action Center tools TODAY to ask your two Senators and one Representative to support a Fiscal Year 2021 budget that:

• Increases funding to $44.7 billion for the National Institutes of Health to fund research to fight diseases including lupus and catch up on previous years of lowered funding.
• Provides $10 million for the Lupus Research Program operated under the Defense Health Program. We need to continue the momentum of the Program's first four years to improve care for the rising numbers of women with lupus in the military and treated at military facilities.
• Increases by $120 million the Food and Drug Administration's budget authority. A science-based, predictable, and efficient FDA helps the pharmaceutical industry innovate and develop new treatments.

Use our Legislative Action Center to contact your legislators by email, phone and/or social media. You can send an easy form email or include your story to show why lupus research is greatly needed for new treatments and a cure.

The Lupus Research Alliance is the world's leading authority
in lupus research.

LRA Urges U.S. Health Officials to Ensure Hydroxychloroquine Supply for Lupus Community

The Lupus Research Alliance (LRA) Scientific Advisory Board Chair Dr. Gary Koretzky sent a strong letter to top federal health officials calling attention to the critical need for hydroxychloroquine to be available for people with lupus who have relied on it for years. The letter was signed by 18 international leaders who represent academia, the pharmaceutical industry and the American College of Rheumatology.

The letter was addressed to: Alex M. Azar II, JD, Secretary, U.S. Department of Health and Human Services; Stephen M. Hahn, MD, Commissioner of Food and Drugs, U.S. Food and Drug Administration; and Anthony S. Fauci, MD, Director, National Institute of Allergy and Infectious Diseases.

FDA Fast-Tracks Potential Lupus Treatment RC18

The LRA is pleased to share good news about a potential lupus treatment. The U.S. Food and Drug Administration granted fast-track designation to RC18, a novel drug in development by RemeGen.

According to the FDA, the purpose of fast-track designation "is to get important new drugs to the patient earlier."

Are Autoimmune Diseases Increasing in the US?

An important study provides compelling evidence that proteins, known as anti-nuclear antibodies (ANA), found in many people with autoimmune diseases have become more common in Americans over time.

These results suggest that people may be becoming at greater risk for developing autoimmune diseases like lupus. The study was recently published in the well-respected journal Arthritis & Rheumatology.

From the Lupus Research Alliance, the world's leading authority
in lupus research.

Dear Friend,

If anything positive has come out of COVID-19, it's that people are more thankful. I certainly feel this way-so I want to express my deepest gratitude to you for your support of the Lupus Research Alliance (LRA).

You always come through! The LRA relies on people who understand the power of science-compassionate people like you who enable us to fund the most pioneering lupus research in the world. Frankly, we can't find answers without you.

So please allow me to remind you that I sent an email about participating in Giving Tuesday Now earlier today. There is still time to participate. But hurry, time is running out!

As I mentioned earlier, I'm committed to not letting COVID-19 interfere with the extraordinary success the LRA has had in changing the very landscape of lupus research-and I hope you will join me! Continue to support the LRA.

Thank you for your continued support of the LRA! And please join us once more with your most generous contribution.

Sincerely,

Brenda Blackmon
Member of the Board

From the Lupus Research Alliance, the world's leading authority
in lupus research.

Take Our Survey - Tell Us What You Think About Joining Lupus Trials

COVID-19 has raised many questions about today's clinical trial process, and the research community is questioning how we can make that process better now and in the future. We ask that you take 10 minutes to fill out our survey to understand your perceptions and knowledge of clinical trials and what impact COVID-19 may be having on your routine medical care and clinical trial participation.

With your feedback, we hope to uncover common concerns and figure out possible solutions to make trials work for you.

Please complete the survey by Sunday, August 9. We plan to share results at our upcoming webcast August 24 on clinical trial innovation led by Lupus Therapeutics, LRA's clinical trial division. Stay tuned for details.

House Approves $10 Million Lupus Research Funding!

We are thrilled to announce that the House of Representatives today passed the 2021 Fiscal Year Defense Appropriations Bill giving $10 million for the Lupus Research Program at the Department of Defense. The House also passed the FY 2021 Labor, Health and Human Services Appropriations Bill providing $47 billion for the National Institutes of Health, an increase of $5.5 billion above FY 2020.

The many, many phone calls and emails you, our LRA advocates, made in March paid off! We''ll keep you posted as the process continues.

Why and how do LRA supporters fundraise effectively for lupus research? Watch this recording of Tuesday's live webcast to find out lots of great ideas and success stories.

And, don't forget to register for the Virtual Walk Event that will bring the global lupus community together on September 12, 2020 at 12:00 PM EST.

From the Lupus Research Alliance, the world's leading authority
in lupus research.

Register | Fundraise | Donate